SECsense Logo

Vistagen Therapeutics, Inc. 8-K Report: Key Developments and Insights

$VTGN
Form 8-K
Filed on: 2025-01-14
Source
Vistagen Therapeutics, Inc. 8-K Report: Key Developments and Insights

Based on the provided section of the financial report, here are the key pieces of information and insights:

  1. Entity Identification:
  • Company Name: Vistagen Therapeutics, Inc.
  • CIK: 0001411685
  • Ticker Symbol: VTGN
  • Exchange: NASDAQ
  • State of Incorporation: Nevada (NV)
  • EIN: 20-5093315
  1. Filing Information:
  • Filing Type: 8-K (current report)
  • Filing Date: January 14, 2025
  • Period Covered: September 23, 2024
  1. Contact Information:
  • Address: 343 Allerton Ave., South San Francisco, CA 94080
  • Phone Number: 650-577-3600
  1. Security Information:
  • Type of Security: Common Stock
  • Par Value: $0.001 per share
  1. Context: The report appears to be a current report (Form 8-K) filed with the SEC, which is typically used to disclose important events or corporate changes that shareholders should be aware of.

Insights:

  • The filing date indicates that this report was submitted shortly after the end of the reporting period, implying timely compliance with SEC regulations.
  • The company's identification as a biotechnology firm (as inferred from its name) may suggest ongoing developments or announcements relevant to its products or research activities that could impact stock performance.
  • The par value of the common stock is low ($0.001), which might reflect a strategy to maintain flexibility in capital structure or could indicate the company's growth stage.
  • Monitoring the developments reported in this 8-K could provide insights into significant corporate actions, such as mergers, acquisitions, financial performance, or changes in management.

This information is critical for investors or stakeholders looking to analyze the financial health and operational developments of Vistagen Therapeutics, Inc.